enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGN) saw a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 216,700 shares, an increase of 38.7% from the August 31st total of 156,200 shares. Currently, 1.3% of the shares of the company are short sold. Based on an average trading volume of 123,800 shares, the short-interest ratio is presently 1.8 days.

enGene Stock Up 10.0 %

Shares of ENGN stock traded up $0.55 during trading hours on Friday, reaching $6.05. 432,716 shares of the stock were exchanged, compared to its average volume of 99,694. enGene has a 12-month low of $4.42 and a 12-month high of $43.00. The business’s fifty day moving average is $7.00 and its two-hundred day moving average is $10.78. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 19.52. The firm has a market capitalization of $267.20 million, a P/E ratio of -3.52 and a beta of -0.68.

enGene (NASDAQ:ENGN) last announced its quarterly earnings data on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. As a group, research analysts expect that enGene will post -1.64 EPS for the current fiscal year.

Institutional Investors Weigh In On enGene

Hedge funds have recently modified their holdings of the company. Altitude Crest Partners Inc. acquired a new position in enGene during the first quarter valued at approximately $2,039,000. SR One Capital Management LP bought a new position in shares of enGene in the second quarter worth $4,715,000. Omega Fund Management LLC acquired a new position in enGene during the 4th quarter valued at about $10,441,000. Logos Global Management LP grew its holdings in shares of enGene by 50.0% during the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after acquiring an additional 400,000 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new stake in shares of enGene in the 1st quarter valued at approximately $17,095,000. 64.16% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ENGN shares. Morgan Stanley reaffirmed an “overweight” rating and set a $40.00 price objective on shares of enGene in a report on Wednesday, September 11th. Oppenheimer restated an “outperform” rating and issued a $30.00 price target on shares of enGene in a report on Tuesday, September 24th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, enGene currently has an average rating of “Buy” and an average price target of $33.67.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.